Everything below concerns freeze-dried powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
== Causes == Conditions that chronically increase the pressure within the abdomen can predispose people to uterine prolapse. This includes chronic obstructive pulmonary disease (COPD), obesity, chronic cough, straining due to chronic constipation, and repetitive heavy lifting. Tobacco smoking has been found to be correlated to pelvic organ prolapse both due to the risk of developing lung conditions that lead to chronic cough or COPD as well as the negative effects of tobacco chemicals on connective tissue.
== Selectivity == While serine/threonine kinases all phosphorylate serine or threonine residues in their substrates, they select specific residues to phosphorylate on the basis of residues that flank the phosphoacceptor site, which together comprise the consensus sequence. Since the consensus sequence residues of a target substrate only make contact with several key amino acids within the catalytic cleft of the kinase (usually through hydrophobic forces and ionic bonds), a kinase is usually not specific to a single substrate, but instead can phosphorylate a whole "substrate family" which share common recognition sequences. While the catalytic domain of these kinases is highly conserved, the sequence variation that is observed in the kinome (the subset of genes in the genome that encode kinases) provides for recognition of distinct substrates. Many kinases are inhibited by a pseudosubstrate that binds to the kinase like a real substrate but lacks the amino acid to be phosphorylated. When the pseudosubstrate is removed, the kinase can perform its normal function.
In certain situations where strong electroosmotic flow toward the cathode is undesirable, the inner surface of the capillary can be coated with polymers, surfactants, or small molecules to reduce electroosmosis to very low levels, restoring the normal direction of migration (anions toward the anode, cations toward the cathode). CE instrumentation typically includes power supplies with reversible polarity, allowing the same instrument to be used in "normal" mode (with EOF and detection near the cathodic end of the capillary) and "reverse" mode (with EOF suppressed or reversed, and detection near the anodic end of the capillary). One of the most common approaches to suppressing EOF, reported by Stellan Hjertén in 1985, is to create a covalently attached layer of linear polyacrylamide. The silica surface of the capillary is first modified with a silane reagent bearing a polymerizable vinyl group (e.g. 3-methacryloxypropyltrimethoxysilane), followed by introduction of acrylamide monomer and a free radical initiator. The acrylamide is polymerized in situ, forming long linear chains, some of which are covalently attached to the wall-bound silane reagent. Numerous other strategies for covalent modification of capillary surfaces exist. Dynamic or adsorbed coatings (which can include polymers or small molecules) are also common. For example, in capillary sequencing of DNA, the sieving polymer (typically polydimethylacrylamide) suppresses electroosmotic flow to very low levels.
Pseudouridine was also detected in the Leishmania donovani genome. 18 pseudouridine modification sites were detected in the peptidyl transferase entry site and in the mRNA entry tunnel in protein translation. These modifications in the parasite lead to increased protein synthesis and growth rate. Pseudouridine in rRNA and tRNA has been shown to fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation. Pseudouridine in snRNA has been shown to enhance spliceosomal RNA-pre-mRNA interaction to facilitate splicing regulation.
(i.e. the deviatoric stress in a Newtonian fluid has no normal stress components), and it has a compressibility term in addition to the incompressible case, which is proportional to the shear viscosity:
Sources: en.wikipedia.org
Freeze branding (sometimes called CryoBranding and the resulting brands, trichoglyphs) is a technique involving a cryogenic coolant instead of heat to produce permanent marks on a variety of animals. The coolant is used to lower the temperature of a branding iron such that its application to shaved skin will permanently alter hair follicles. The intense cold destroys the pigmentation apparatus in the animal's hair follicles, leaving all subsequent hair growth without color. This creates a high-contrast, permanent mark in the shape of the branding iron's head. A longer application of the cold iron can also permanently remove hair and is used on white or pale animals. In these cases, the loss of hair leaves a patch of hairless skin in the shape of the brand. The technique is most commonly used as an identification mark for ownership, although it finds application in biological studies of wild animals as well. Freeze branding is most often used on mammalian livestock with smooth coats such as cattle, donkeys and horses although it has been used successfully on a wide variety of other mammals, as well as frogs, newts, snakes, fish and even crabs. Freeze branding is often seen as a more ethical alternative to traditional hot branding, so much so that experts have called for the prohibition of hot branding in favor of the cryogenic technique. Hot branding involves the use of an iron stamp heated to around 500 ºC (930 ºF), a temperature sufficient to destroy all three layers of an animal's skin and leave a permanent scar.
=== Criminal justice and cannabis legalization === In 2014, Newsom was the only statewide politician to endorse California Proposition 47, legislation that recategorized certain nonviolent offenses from felonies to misdemeanors, including shoplifting, grand theft, and receiving stolen property valued at under $950. Voters passed the measure on November 4, 2014. In July 2015, Newsom released the Blue Ribbon Commission on Marijuana Policy's final report, which he had convened with the American Civil Liberties Union of California in 2013. The report's recommendations to regulate cannabis were intended to inform a legalization measure on the November 2016 ballot. Newsom supported the resulting measure, Proposition 64, which legalized cannabis use and cultivation for California state residents who are 21 or older. On February 24, 2017, in response to pro-enforcement statements by White House Press Secretary Sean Spicer, Newsom sent Attorney General Jeff Sessions and President Donald Trump a letter urging them not to increase federal enforcement against recreational cannabis firms opening in California. He wrote: "The government must not strip the legal and publicly supported industry of its business and hand it back to drug cartels and criminals ... Dealers don't card kids.
Apart from fluorescence microscopy, SNAP-tag and CLIP-tag have proven useful in the elucidation of numerous biological processes, including the identification of multiprotein complexes using various approaches such as FRET, cross-linking, proximity ligation assay, as well as the purification of insulin secretory granules of distinct age by doing pulse-chase experiments Other application include the measurement of protein half-lives in vivo, and small molecule-protein interactions. SNAP-tag® is a registered trademark of New England Biolabs, Inc. CLIP-tag™ is a trademark of New England Biolabs, Inc.
=== Childhood === The newborn's vulva may be swollen or enlarged as a result of having been exposed, via the placenta, to her mother's increased levels of hormones. The labia majora are closed. These changes disappear over the first few months. During childhood before puberty, the lack of estrogen can cause the labia to become sticky and to ultimately join firmly together. This condition is known as labial fusion and is rarely found after puberty when estrogen production has increased.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.